Last reviewed · How we verify

RX0041 4%

Pharmaceutical Project Solutions, Inc. · Phase 3 active Small molecule

This drug is a small molecule that targets the serotonin receptor.

This drug is a small molecule that targets the serotonin receptor. Used for Major depressive disorder, Generalized anxiety disorder.

At a glance

Generic nameRX0041 4%
Also known asTopical Anesthetic
SponsorPharmaceutical Project Solutions, Inc.
Drug classSSRI
Target5-HT receptor
ModalitySmall molecule
Therapeutic areaPsychiatry
PhasePhase 3

Mechanism of action

It works by selectively binding to the serotonin receptor, which leads to a decrease in serotonin levels in the brain. This decrease in serotonin levels is associated with a reduction in anxiety symptoms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results